US OptionsDetailed Quotes
COSM250117C1500
- 0.05
- 0.000.00%
15min DelayClose Dec 31 16:00 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume16 Open Interest1.50Strike Price0.00Turnover351.29%IV131.69%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier16DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.2371Delta0.6225Gamma13.38Leverage Ratio-0.0047Theta0.0000Rho3.17Eff Leverage0.0004Vega
Cosmos Health Stock Discussion
Cosmos Health CEO Greg Siokas and CFO George Terzis Collectively Increase Stake by 343,000 Shares Valued at $200,000
Monday, 23rd December at 9:25 am
CHICAGO, IL / ACCESSWIRE / December 23, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ: COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, ...
Cosmos Health Integrates Bitcoin and Ethereum as Treasury Reserve Assets
Cosmos Health (NASDAQ:COSM) has announced the integration of Bitcoin and Ethereum as part of its treasury reserve assets. This strategic move aligns with the company's investment in new technologies, following their recent acquisition of Cloudscreen, an AI-driven drug repurposing platform. The company aims to diversify its balance sheet through cryptocurrency and blockchain-related assets, ...
Cosmos Health's Subsidiary CosmoFarm Achieves Record Revenue, Up 8.62% to $43 Million YTD 2024, with Gross Profit Rising 21%
Positive
Record revenue of $43 million YTD 2024, up 8.62% year-over-year
Gross profit increased by 21%
Projected to exceed $52 million in annualized revenue
Expanded customer base to over 1,500 pharmacies
Negative
None.
All the positive news and then this shit tanked! 😔
Cosmos Health Reports Strong 160% Increase in 2024 YTD Sales on Amazon UK for Its Proprietary Brands
Cosmos Health Inc. (NASDAQ:COSM) has reported a significant 160% increase in sales of its proprietary brands on Amazon UK for the year-to-date 2024. Sales have risen to $596,000 from $230,000 during the same period in 2023. The company's CEO, Greg Siokas, expressed satisfaction with the strong reception of their brands in the UK market and anticipates continued growth...
Cosmos Health Receives Initial Orders Exceeding $500,000 for C-Scrub in the UK; Future Orders Booked at Accelerated Pace with Strong Profitability Anticipated Due to High Profit Margins
Cosmos Health Expands Global Presence into India, a Market with Over 1.4Bn People, Through Exclusive Agreement to Distribute Virax Biolabs' Mpox PCR Detection Kits
Cosmos Health (NASDAQ:COSM) has entered an exclusive agreement with Virax Biolabs to distribute mpox virus real-time PCR detection kits across India, a market with over 1.4 billion people. This expansion follows a recent second reported case of mpox in India on September 18, 2024. The agreement positions C...
Cosmos Health Enters Development Phase for CCDL24, an Innovative Multitargeting Product for Gastrointestinal Disorders, with a Market Size Valued at Over $37.5 Billion
Cosmos Health (NASDAQ:COSM) has entered the development phase for CCDL24, an innovative treatment for gastrointestinal (GI) disorders. The product utilizes advanced biopolymeric grids from natural ingredients to encapsulate bioactive molecules, enhancing drug efficacy at targeted sites. Current efforts...
No comment yet